ClinicalTrials.gg
RecruitingNCT06249178Updated Dec 29, 2025

EV Based Platform for Monitoring Therapeutics Response During Pregnancy (ARISE)

An observational study in Preeclampsia, sponsored by Ohio State University. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by Ohio State University · Observational

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Pre-Eclampsia by Ohio State University — 4 open to participants now, 4 under way, none of them phase 3. Pre-Eclampsia · Ohio State University.

Started
2024
with 1 other
Observational
5 of 11
2 open now
Registered
8th of 11
by date

Among the 11 studies in Pre-Eclampsia by Ohio State University, this one is one of 2 that started in 2024, is one of 5 observational ones, and was the 8th registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

4 of the 11 studies in Pre-Eclampsia by Ohio State University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Pre-Eclampsia by Ohio State University, or all of them as a file.
02

Study summary

The goal of this prospective observational cohort study of pregnant people at-risk of preeclampsia receiving aspirin as part of clinical care or a planned randomized controlled trial of 81mg vs. 162mg of aspirin is to generate proteomic data to show a distinct maternal and fetal Extracellular Vesicle (EV) proteome profile with aspirin treatment, and develop and validate a multi-marker panel for the monitoring of placental function in people at-risk of Preeclampsia and in response to aspirin treatment. The primary research question is:

1. Does the maternal and fetal Positive for Placental Alkaline Phosphatase (PLAP+) Extracellular Vesicle (EV) proteome profile in the 2nd and 3rd trimester of pregnancy differ between people who receive aspirin and develop (or not) preeclampsia?

Participants will be asked to give blood samples up to four times during and at the end of their pregnancy.

Read the detailed description

Pregnant and lactating people remain therapeutic orphans as they are excluded from the vast majority of clinical drug development and therapeutic trials. Moreover, current practices in drug evaluation in pregnancy have been hindered by the lack of effective biomarkers and innovative study designs. There is a need to develop novel placental-specific biomarkers in order to assess placental function and response to therapeutics, as a way to inform on their safety and efficacy. An example of these novel biomarkers is placental (fetal) specific extracellular vesicles (EVs). Recent advances in characterizing the cargo content of these EVs demonstrated their potential to be used as placental biomarkers. Fourteen proteins found in EVs significantly correlated with aspirin use (FDR\<0.1) in at-risk people, but that more power is needed to confidently assess the relationship with aspirin dosage and pregnancy outcomes. In addition, prior studies showed that aspirin affects endothelial and trophoblast cells, thus potentially modulating exosome derived from these cells and their cargo contents.

The main goal is to develop a novel platform using exosome profiling, as novel biomarkers, to monitor placental mediated adverse pregnancy outcomes and response to therapeutics.

Specific Aim 1: Develop and validate a multi-marker panel/Extracellular Vesicle (EV) proteome profile (maternal and fetal) for monitoring of placental/fetal membrane function in people at-risk of Preeclampsia (PE) and in response to aspirin treatment.

Specific Aim 2: Demonstrate that maternal and fetal Positive for Placental Alkaline Phosphatase (PLAP+) EV proteome profile in the 2nd and 3rd trimester of pregnancy differ between people who develop (or not) preeclampsia and correlate with aspirin dose and salicylic acid concentrations.

Specific Aim 3: Demonstrate that the changes in maternal and fetal EV proteome profiles (baseline to 2nd-3rd trimester) correlate with the changes in inflammatory and angiogenic imbalance profiles associated with PE, and with other clinical outcomes such as Preterm Birth (PTB) and Fetal Growth Restriction (FGR).

03

Conditions studied

  • Preeclampsia

Browse trials for

Keywords

  • Extracellular vesicles proteome profile
  • Aspirin treatment
  • Pregnancy
  • Preeclampsia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Pregnant women greater than 18 years of age at risk of preeclampsia (PE), receiving aspirin to prevent PE or a candidate to receive aspirin.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants will be eligible to participate if they meet the following study inclusion criteria:

  1. pregnant individuals age ≥18 years
  2. enrolled ≤16 6/7 weeks of gestation based on the best obstetric estimate as defined by ACOG criteria
  3. singleton live intrauterine gestation
  4. Any of the following:

    1. At least one of the high-risk criteria for HDP (per US Preventive Services Task Force Recommendation Statement [USPSTF]); i) any prior pregnancy complicated by Preeclampsia ii) current pregnancy complicated by chronic hypertension iii) chronic kidney disease iv) disease (e.g., antiphospholipid syndrome, lupus) or
    2. Two or more moderate-risk criteria for HDP (per USPSTF); i) nulliparity (no prior delivery at or after 20 weeks 0 days of gestation) ii) obesity ( ≥30 kg/m2 at time of enrollment) iii) age ≥35 years (at time of expected estimated due date) iv) Black race v) Low income vi) Personal risk factors (previous pregnancy with low birth weight or SGA infant, previous adverse pregnancy outcome [unexplained stillbirth], placental abruption, interval >10 years between pregnancies).

      vii) Pregnancy after in vitro conception viii) family history of preeclampsia ( i.e., mother or sister)

    3. or participating in another clinical RCT of 81mg vs. 162mg aspirin for prevention of hypertensive disorders of pregnancy

Exclusion criteria

Exclusion Criteria:

  1. age \< 18 years,
  2. involuntarily confined or detained
  3. considered as having a diminished decision-making capacity
  4. multifetal gestation
  5. pregestational diabetes mellitus or gestational diabetes diagnosed \< 20 weeks due to the impact on exosome response
  6. known or suspected fetal aneuploidy or major congenital abnormality, fetal demise, or planned pregnancy termination
  7. known allergy or to aspirin or any medical condition where aspirin is (e.g., peptic ulcer disease, nasal polyps, NSAID-induced asthma, gastrointestinal bleeding, G6PD deficiency, severe hepatic dysfunction, bleeding disorders)
  8. plan to deliver at another center or participating in another intervention study that influences the primary outcome in this study, without prior approval
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. multi-marker panel

    Multi-marker panel (list of proteins) associated with placental function in people at-risk of PE and in response to aspirin treatment.

    Time frame: From enrollment till delivery; up to 29 weeks

Secondary outcomes

  1. Preeclampsia

    Preeclampsia defined according to ACOG guidelines

    Time frame: From enrollment to deliver; up to 29 weeks

  2. Preterm birth < 37 weeks gestation

    Delivery before 37 0/7 weeks gestation

    Time frame: From enrollment to deliver; up to 25 weeks

  3. Preterm birth < 34 weeks gestation

    Delivery before 34 0/7 weeks gestation

    Time frame: From enrollment to deliver; up to 22 weeks

  4. Preeclampsia with severe features

    Preeclampsia with severe features as defined by the ACOG diagnostic criteria

    Time frame: From enrollment to deliver; up to 29 weeks

  5. Gestational hypertension

    Gestational hypertension defined as new onset hypertension in the absence of accompanying proteinuria or other features of preeclampsia

    Time frame: From enrollment to deliver, up to 29 weeks

  6. Fetal growth restriction

    Estimated fetal weight or abdominal circumference \<10%

    Time frame: From enrollment to deliver; up to 29 weeks

  7. Birthweight

    weight of newborn at time of birth

    Time frame: at delivery

  8. PlGF

    Serum concentration of PlGF in the third trimester

    Time frame: 28 to 41 weeks

  9. sFLT-1

    Serum concentration of sFLT-1 in the third trimester

    Time frame: 28 to 41 weeks

07

Study locations

1 of 1 sites recruiting
  • The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine
    Columbus, Ohio 43210, United States
    Recruiting
    • Maged Costantine, MD, MBA · ContactMaged.Costantine@osumc.edu · 614-293-2222
    • Kara Rood, MD · ContactKara.Rood@osumc.edu · 614-293-8045
    • Kara Rood, MD · Sub investigator
    • Mitch Phelps, PhD · Sub investigator
    • Brian Searle, PhD · Sub investigator
    • Damien Wilburn, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Sep 2028, 49 months after the start.

Of 191 non-industry observational studies under Pre-Eclampsia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 56. This study's planned 49 months is above that.

Counting every sponsor, half of 200 studies reached it within 30 months; a quarter within 11 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2024
First posted
Feb 8, 2024
StartActual
Jul 2, 2024
Primary completionEst.
Sep 1, 2028
CompletionEst.
Sep 1, 2028
Last update
Dec 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06249178
Responsible party
Maged Costantine (MD, MBA, Professor, Ohio State University) — Principal investigator
First posted
Feb 8, 2024
Start date
Jul 2, 2024
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Dec 29, 2025

Study contacts

Maged Costantine, MD, MBA
Contact
Maged.Costantine@osumc.edu
614-293-2222
Kara Rood, MD
Contact
Kara.Rood@osumc.edu
614-293-8045
Maged Costantine, MD, MBA
principal investigator · Ohio State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion